All News

The common wisdom among technology-policy analysts is that Europe is bad at transferring technology out of its great universities and into the commercial world. A new study asserts that, by some measures, Europe may actually outperform the U.S., Canada and Australia.

A new report in the USA will be the basis for some of the work on the health and safety of nanotechnology.

The latest announcement from BASF Venture Capital America Inc. brings back memories of the dash for energy R&D 30 years ago.

A battle between IBM and Microsoft for the hearts and minds of tech start-ups took a new turn as IBM announced free technical-development help to promising VC-backed firms.

Milken Institute, a California-based think-tank founded by famous financier Michael Milken, published earlier this week a report on global trends in university biotechnology transfer. This is an impressive piece of work, carried out by a research team of nine and drawing on every conceivable source of data.

A new study shows that universities in the USA still rule the roost when it comes to biotech research, not to mention turning it into cash.

This week, Science|Business launches an initiative to improve the process of innovation in Europe – an online marketplace to link scientists and industry.

US institutions are dominant in a survey of bio tech transfer published by the Miliken Foundation covering publications, patenting and tech transfer outcomes.

A transatlantic collaboration that will systematically uncover the function of human genes and make the findings public got under way earlier this month.

Just over half of Europe’s scientifically qualified work force is female, but fewer than one in three of Europe’s professional scientists and technologists are women...

Germany is poised to begin the great sell-off of its university hospitals. What will this mean for the research and development they carry out?

An international partnership has started to build a large-scale public infrastructure for sharing research information across Europe.

The EU backed Innovative Medicines Initiative has updated its strategic research agenda, outlining strategies to overcome 'bottlenecks' to efficient R&D for new medicines.